Tag: file

Wuxi, China, June 12, 2026 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd., (NASDAQ: BYAH) an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), today announced that it has entered into a securities purchase agreement with several investors for the sales of the Company’s securities in a registered direct offering (the “Offering”) consisting of up to 1,133,332 of the Company’s Class A ordinary shares, par value $0.001 each (the “Shares”), and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 200,000 Class A ordinary shares (the “Warrant Shares”), at a combined purchase price of $1.50 per Share and Pre-Funded Warrant. The gross proceeds to the Company from this Offering are expected to be approximately $2.0 million.

LOS ANGELES, June 12, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion.

Sydney, Nouvelle-Galles du Sud, 12 juin 2026 (GLOBE NEWSWIRE) -- Le Groupe CSL (« CSL »), un chef de file mondial en matière de transport maritime responsable, et Adbri annoncent la livraison du MV Yampu, le premier vraquier autodéchargeant au monde propulsé par batteries. Le navire a été officiellement livré au chantier naval de Jiangjiang Nanyang le 5 juin 2026 et a depuis pris la mer pour son voyage inaugural afin de commencer ses opérations pour Adbri à Birkenhead, en Australie-Méridionale.

Shell announces pause in share buyback programme

Basel, June 12, 2026 – Novartis today presented data from the RemIND trial at the European Academy of Allergy and Clinical Immunology (EAACI) Congress showing that Rhapsido^®  (remibrutinib) met its primary endpoints across the three most common chronic inducible urticaria (CIndU) subtypes, becoming the first-ever treatment to demonstrate efficacy in a global Phase III CIndU clinical trial⁷. In the RemIND trial, higher rates of complete responses were observed at week 12, with responses seen as early as week 2 in two subtypes. These results demonstrate that Rhapsido may provide sustained relief for patients whose disease remains inadequately controlled after treatment with second-generation H1-antihistamines⁷.

“Chronic inducible urticaria (CIndU) is a form of chronic hives in which everyday triggers—such as pressure, heat, cold, or sunlight—can lead to itchy wheals, and there are currently no approved targeted treatment options,” said Prof. Dr. med. Martin Metz, Deputy Director, Institute of Allergology, Charité–Universitätsmedizin Berlin, Germany. “The RemIND results across the three most common CIndU subtypes highlight the potential of Rhapsido as an important new treatment option for patients with significant unmet need.”

The three most prevalent CIndU subtypes are symptomatic dermographism (SD), cold urticaria, and cholinergic urticaria, with SD being the most common⁸. Novartis has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Rhapsido for the treatment of SD subtype and will continue additional filings to health authorities globally throughout 2026. Rhapsido is approved for use in the U.S., European Union, China and several other countries for the treatment of chronic spontaneous urticaria (CSU), in adult patients with inadequate response to H1-antihistamines.

“Rhapsido significantly improves symptom control for patients living with the three most common subtypes of chronic inducible urticaria, and it has the potential to become the first approved targeted therapy. This is a major step forward for CIndU patients who have limited options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “The CIndU data presented today are consistent with Rhapsido’s proven efficacy and favorable safety profile in chronic spontaneous urticaria and demonstrate Novartis’ commitment to developing truly meaningful innovation for patients with complex immune-mediated diseases.”

Primary endpoint results at Week 12 in the RemIND trial¹

DALLAS, June 11, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.^® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today that it has entered into securities purchase agreements for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per share of common stock (or pre-funded warrant in lieu thereof) and associated preferred investment options in a private placement priced at-the-market under Nasdaq rules.

New York, New York, June 11, 2026 (GLOBE NEWSWIRE) -- Ocean Capital Acquisition Corporation, a blank check company incorporated in the British Virgin Islands as an exempted company with limited liability (the “Company”), today announced the closing of its previously announced initial public offering (the “IPO” or this “Offering”) of 10,000,000 units (the “Units”) at an offering price of $10.00 per Unit. Each Unit consists of one ordinary share, one redeemable warrant, and one right to receive one ordinary share upon the consummation of an initial business combination. Each redeemable warrant entitles the holder thereof to purchase one ordinary share of the Company at a price of $11.50 per share, subject to certain adjustments.

EDISON, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ: EOSE) ("Eos" or the “Company”), America’s leading innovator in designing, manufacturing, and providing zinc-based long duration energy storage (LDES) systems sourced and manufactured in the United States, today announced certain terms of a distribution (the "Rights Distribution") of subscription rights to holders of its common stock and holders of its warrants to purchase common stock issued on April 14, 2023, May 17, 2023, December 19, 2023 and November 21, 2025 (collectively, “Eligible Holders”) to acquire shares of the Company’s common stock and warrants to purchase shares of the Company’s common stock in a rights offering to fund the Company’s previously announced capital contribution in the Frontier Power USA joint venture.

Launch places Sports.com Predict inside the Sports.com ecosystem at the start of the World Cup, with additional live-sport visibility through E1 Team Miami and the UIM E1 World Championship

NEW ORLEANS, June 11, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 17, 2026 to file lead plaintiff applications in a securities class action lawsuit against Sportradar Group AG (NasdaqGS: SRAD) (“Sportradar” or the “Company”), if they purchased or otherwise acquired the Company’s Class A ordinary shares between November 7, 2024 and April 21, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

Industry veterans bring deep expertise in advanced reactor deployment, nuclear operations and regulatory licensing to support company’s U.S. growth